Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: results from the NCI-MATCH trial (EAY131) subprotocol W

YK Chae, F Hong, C Vaklavas, HH Cheng… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile–
driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with …
被引用次数：126 相关文章

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W.

YK Chae, F Hong, C Vaklavas, HH Cheng… - Journal of Clinical …, 2020 - europepmc.org
Purpose NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile-
driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with …

Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: Results from the NCI-MATCH Trial (EAY131) subprotocol W

YK Chae, F Hong, C Vaklavas… - Journal of Clinical …, 2020 - scholars.northwestern.edu
Purpose: NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile-
driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with …

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

YK Chae, F Hong, C Vaklavas… - Journal of clinical …, 2020 - pubmed.ncbi.nlm.nih.gov
Purpose NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile-
driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with …

Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: Results from the NCI-MATCH Trial (EAY131) subprotocol W

YK Chae, F Hong, C Vaklavas… - Journal of Clinical …, 2020 - mayoclinic.elsevierpure.com
Purpose: NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile-
driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with …

Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

YK Chae, F Hong, C Vaklavas, HH Cheng… - Journal of Clinical …, 2020 - cir.nii.ac.jp
抄録< jats: sec>< jats: title> PURPOSE</jats: title>< jats: p> NCI-MATCH is a nationwide,
histology-agnostic, signal-finding, molecular profile–driven trial for patients with refractory …

Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: Results from the NCI-MATCH Trial (EAY131) subprotocol W

YK Chae, F Hong, C Vaklavas… - Journal of …, 2020 - utsouthwestern.elsevierpure.com
Purpose: NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile-
driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with …
[HTML] nih.gov

[HTML][HTML] Phase II Study of AZD4547 in Patients With Tumors Harboring Aberrations in the FGFR Pathway: Results From the NCI-MATCH Trial (EAY131) Subprotocol W

YK Chae, F Hong, C Vaklavas, HH Cheng… - Journal of Clinical …, 2020 - ncbi.nlm.nih.gov
PURPOSE NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile–
driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with …

Phase II study of AZD4547 in patients with tumors harboring aberrations in the FGFR pathway: Results from the NCI-MATCH Trial (EAY131) subprotocol W

YK Chae, F Hong, C Vaklavas… - Journal of …, 2020 - mdanderson.elsevierpure.com
Purpose: NCI-MATCH is a nationwide, histology-agnostic, signal-finding, molecular profile-
driven trial for patients with refractory cancers, lymphomas, or myelomas. Patients with …